A phase IV, single centre, open-label study to investigate the persistence of antibodies six years after priming immunisation with meningococcal C conjugate vaccine induction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix) vaccine, in healthy children six to 12 years of age

Trial Profile

A phase IV, single centre, open-label study to investigate the persistence of antibodies six years after priming immunisation with meningococcal C conjugate vaccine induction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix) vaccine, in healthy children six to 12 years of age

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary)
  • Indications Haemophilus infections; Meningococcal group C infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Jul 2010 New source identified and integrated (United Kingdom Clinical Research Network).
    • 10 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top